Overall survival for patients with de novo CD5⁺ DLBCL and with cyclin D1⁺ MCL.

De novo CD5⁺ DLBCL showed an initially more aggressive clinical course than MCL, but the survival curve crossed that of MCL 5 years after diagnosis and showed superior survival thereafter.